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Abstract
Objective—This study identified socio-demographic, substance use, and multiple opioid 
prescriber and dispenser risk factors among drug overdose decedents in Rhode Island (RI), in 
response to an increase in overdose deaths (OD) involving fentanyl.
Methods—This cross-sectional investigation comprised all ODs reviewed by RI’s Office of the 
State Medical Examiners (OSME) during January 2012–March 2014. Data for 536 decedents were 
abstracted from OSME’s charts, death certificates, toxicology reports, and Prescription Monitoring 
Program (PMP) databases. Decedents whose cause of death involved illicit-fentanyl (N=69) were 
compared to decedents whose cause of deaths did not involve fentanyl (N=467).
Results—Illicit-fentanyl-decedents were younger than other-drug decedents (p=0.005). While 
more other-drug than illicit-fentanyl decedents had postmortem toxicological evidence of 
consuming heroin (31.9% vs. 19.8%; p<0.001) and various pharmaceutical substances (p=0.002–
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0.027), third-party reports indicated more recent heroin use among illicit-fentanyl decedents 
(62.3% v. 45.6%; p=0.002). Approximately 35% of decedents filled an opioid prescription within 
90 days of death; of these, one-third had a mean daily dosage of >100 morphine milligram 
equivalents. Most decedents’ opioid prescriptions were filled at 1–2 dispensers (83.9%), and 
written by 1–2 prescribers (75.8%). Notably, 29.2% of illicit-fentanyl and 10.5% of other-drug 
decedents filled prescriptions for buprenorphine, used to treat opioid use disorders.
Conclusions—Illicit-fentanyl deaths frequently involved other illicit drugs (e.g., cocaine, 
heroin). The proportion of all decedents acquiring >100 MME/day prescription dosages written 
and/or filled by few prescribers and dispensers is concerning. To protect patients, prescribers and 
dispensers should review PMP records and substance abuse history prior to providing opioids.
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Introduction
From 2009 to 2012, Rhode Island (RI) experienced a steady increase in drug overdose (OD) 
deaths. (1) Most involved non-prescription, illicit drugs (e.g., heroin, cocaine), which 
accounted for 53% of all ODs reported in 2012 (N=183). (1) In 2013, a small (n=14) 
temporary increase in ODs from acetyl fentanyl – an illegally produced opioid analog – was 
detected in northern RI. (2) Subsequently during January 2014, RI experienced twice as 
many ODs as in January of previous years. These deaths were mostly among people who 
inject drugs, and involved a different synthetic opioid – fentanyl.
First synthesized in the 1960s as a general anesthetic, (3) fentanyl is 50–100 times more 
potent than morphine and 30–50 times more potent than heroin (4). By 1990, and coinciding 
with physicians being encouraged to prescribe stronger analgesics (5), fentanyl was initially 
approved as an analgesic for cancer pain and then expanded to treat chronic pain. Between 
1999 and 2002, the annual number of fentanyl prescriptions in the U.S. increased 150%, 
reaching 4.6 million. (6) Today, fentanyl is used for severe, chronic pain control.
As with other pharmaceutical opioids, fentanyl can be abused and has contributed to the 
national epidemic of drug poisoning deaths. (5) Additionally, illicitly manufactured fentanyl 
– produced by clandestine laboratories since the late 1970s and commonly consumed by 
heroin users – has been associated with ODs. (7) Between April 2005 and March 2007, over 
1,000 ODs involving illicitly manufactured fentanyl were identified in New Jersey; 
Maryland; Chicago, Illinois; Detroit, Michigan; and Philadelphia, Pennsylvania. (8) The 
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desire for higher potency opioids in the face of heroin’s declining purity led to the 
distribution of fentanyl and fentanyl-laced heroin, with a subsequent spike in illicit fentanyl 
ODs throughout the 2000s. (9, 10) Heroin abuse often occurs in the broader context of 
polysubstance use, especially prescription opioids and cocaine. (11)
Study Purpose
In February 2014, the Rhode Island Department of Health (RIDOH) requested the Centers 
for Disease Control and Prevention’s (CDC) assistance in defining and characterizing a 
spike in ODs involving fentanyl. This study explored three types of risk factors for these 
ODs: a) socio-demographic characteristics; b) substance use and abuse, especially opioid 
abuse; and c) visiting multiple prescribers and dispensers to obtain opioid prescriptions 
(considered multiple provider episodes). Findings may help RIDOH target educational 
messages and review their OD prevention strategies. Based on expert advice from local and 
federal law enforcement, health care, public health, and drug rehabilitation and treatment 
professionals, it was hypothesized that OD deaths involving fentanyl were associated with 
illicit substance use.
Methods
This cross-sectional study was conducted as part of an epidemiological public health 
emergency investigation, in response to the increase in OD deaths involving fentanyl 
reported in RI between November 2013 and March 2014. As such, CDC’s National Center 
for Injury Prevention and Control determined that human research regulations did not apply.
Study Sample
The study population consisted of all ODs reviewed by the RI Office of the State Medical 
Examiners (OSME) between January 1, 2012 and March 31, 2014, and whose reported 
manner of death was accidental, pending determination or undetermined (N=630). This 
expanded time-frame allowed for the assessment of whether the increase in fentanyl-related 
deaths constituted an outbreak. Children ages 0–15 years (n=9), in absentia medical 
examiner reviews (n=15), pending cases that were ad hoc determined by the Chief Medical 
Examiner not to be ODs (n=40), and suicides (n=40) were excluded. The final sample size 
was 536 decedents (Figure 1).
Data Sources
This study comprised data from four RIDOH data sources: a) OSME’s charts (electronic and 
hardcopy); b) RI Office of Vital Records’ death certificates; c) RI State Health Laboratory 
toxicology reports; and d) RI’s Prescription Monitoring Program (PMP) database.
OSME’s charts contained socio-demographic, incident, autopsy, toxicology, and third party 
reports of drug use for each decedent. OSME compiled this information from medical 
examiners’ (ME) reports, toxicology reports, emergency medical services and/or hospital 
reports, police reports, medical records, and other information provided to or requested by 
the ME to determine the cause of death. RI has a centralized ME system. All autopsy reports 
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are reviewed by the Chief ME, who certifies the cause of death based on the advice provided 
by the lead ME for each case.
Death certificates contained socio-demographic information on the decedent. Toxicology 
reports contained preliminary and confirmatory results of any toxicology tests performed on 
postmortem samples collected during autopsy or external inspection, and/or available 
antemortem samples collected during terminal hospitalizations, when the decedent was 
hospitalized for more than a few minutes.
RI’s PMP database contained information on any prescriptions filled by the decedents at RI 
pharmacies or dispensers (i.e., product, strength, quantity, days, prescriber, pharmacy). All 
RI pharmacies and mail-order pharmacies licensed to do business in RI have been required 
to report Schedule II-IV prescription dispensing information (e.g., opioids) to the RI PMP 
system since July 1, 2013. Physicians are able to access this system to review their patients’ 
prior prescriptions, as a tool to prevent overprescribing and drug diversion. (12, 13) Only 
prescriptions filled within 90 days of the decedent’s date of death were considered for this 
study.
Definitions
Comparison groups—Illicit-fentanyl deaths included decedents for whom fentanyl was 
listed as an official cause of death or as a contributor on the final autopsy report provided by 
RI OSME, yet were not prescribed fentanyl. These decedents also included decedents for 
whom the cause of death was pending or non-specific, and preliminary toxicology reports 
identified fentanyl levels to be above the RI OSME working cutoff detection limit (i.e., 
enzyme-linked immunosorbent assay (ELISA) > 2 ng/ml), which also allows for the 
detection of fentanyl analogs (14). Consistent with the study’s hypothesis and expert advice, 
decedents who filled at least one fentanyl prescription within 90 days of death were 
excluded from the fentanyl decedents group; only decedents whose deaths involved illicitly 
produced or acquired fentanyl remained in this group. Other-drug deaths included 
decedents for whom illicit fentanyl was not listed as an official cause of death or a 
contributor on the final autopsy report. These decedents also included those for whom the 
final cause of death was pending or non-specific, and fentanyl was not detected in 
toxicology analyses, as well as all decedents who filled fentanyl prescriptions within 90 days 
of death.
Prescription-related variables—Morphine milligram equivalents per day (MME/
day) refers to the average morphine milligram equivalents prescribed for daily use, based on 
all opioid prescriptions dispensed and reported to the PMP system within 90 days of a 
decedents’ date of death. The MME/day for a given prescription is calculated by multiplying 
an MME conversion factor assigned to each opioid product’s National Drug Code (15) by 
the strength of the product and the number of units prescribed per day (i.e., 
Strength*(Quantity/Days)*MME Conversion Factor). The number of units prescribed per 
day is found in the PMP; the MME conversion factors and strengths were obtained from a 
file compiled by CDC that lists opioids, benzodiazepines, muscle relaxants, and other drugs 
of interest to those studying prescription drug OD. Analyses included only the products 
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listed in the CDC MME file (16); elixirs and other cough/cold medications, injectables, and 
opioids infrequently used in outpatient settings were excluded. A decedent was considered 
to be at increased risk for drug overdose if his/her average MME/day was greater than 
100, a frequently utilized cutoff for increased overdose risk (17, 18, 19, 20).
Prescriber refers to a physician or other health care worker licensed to prescribe opioid 
medications in the US, and who was identified in PMP records as having prescribed opioid 
prescriptions to at least one decedent within 90 days death. Dispenser refers to a pharmacy 
or other establishment authorized to store and dispense opioid prescriptions in the US, which 
was identified in PMP records as having dispensed at least one opioid prescription to 
decedents within 90 days of death. Multiple provider episode refers to a decedent filling 
opioid prescriptions provided by 3 or more prescribers, or 3 or more dispensers, within 90 
days of death.
Toxicology variables—Preliminary (i.e., ELISA) and confirmatory toxicology test results 
identified substances present in decedents’ bodies at the time of death or terminal 
admission to a hospital. This includes illicit substances (i.e., methamphetamine, cocaine, 6-
Monoacetylmorphine (6MAM, a heroin metabolite), and heroin); pharmaceutical 
substances, which may have been used either illicitly or for legitimate medical purposes 
(i.e., acetaminophen, benzodiazepines, carisoprodol, codeine, methadone, morphine, 
oxycodone, tricyclic antidepressants, and zolpidem); fentanyl-related substances (i.e., 
acetyl fentanyl, fentanyl, 4-anilino-N-phenethyl-4-piperidine (ANPP, associated with illicit 
fentanyl manufacture)); and opiates, which includes both illicit and pharmaceutical 
products. Since there is no specific toxicology test for heroin, its presence was defined as 
postmortem toxicological evidence of morphine and at least one of the following 
requirements: postmortem toxicological evidence of codeine or 6MAM in decedent’s body, 
presence of track marks in decedent’s body, or presence of injection drug paraphernalia at 
the death scene. An aggregate non-fentanyl-related illicit substance variable was defined 
as a combined measure of the presence of any non-fentanyl illicit substances on the 
decedent’s remains, excluding all pharmaceutical substances.
Recent substance-use variables—Reports of decedents’ recent substance use was 
categorized as prescription drug use (i.e., antidepressant, benzodiazepines, antipsychotics, 
anticonvulsants, sedative, other) or illicit drug use; the latter is further categorized as any 
type (i.e., heroin, cocaine, marijuana, methamphetamines, injection drug use, prescription 
drugs for non-medical purposes, other) or specifically heroin. This information is based on 
third-party reports (e.g., family, friends, medical records) recorded in decedent’s OSME 
charts.
Socio-demographic variables—Decedents were also described in terms of their age 
group (i.e., 17–20, 21–25, 26–35, 36–45, 46–55, 56–65, over 65 years), sex (i.e., female, 
male, unknown), race and ethnicity (i.e., non-Hispanic black, non-Hispanic white, 
Hispanic, other), marital status (i.e., divorced/widowed, married, single, unknown), and 
veteran status (i.e., no, yes, unknown).
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Data Collection and Analyses
To reduce data entry errors, an electronic data abstraction form to collect data from OSME 
charts was developed utilizing Epi Info 7 software. (21) Individual PMP data files were 
downloaded for each decedent from the PMP online system. All data sources were linked 
based on the unique identifying number assigned to each individual. Data were de-identified 
for analyses.
Descriptive analyses were conducted for all deaths. Frequencies and proportions were 
calculated for all socio-demographic, substance use/abuse, and multiple provider episode 
variables. Bivariate comparisons between potential risk factors and illicit-fentanyl and other-
drug decedents were examined using chi-square or Fisher’s Exact Tests, and T-tests assessed 
significant statistical differences (i.e., p<0.05) in proportions and means, respectively. The 
trend of all deaths, highlighting those involving illicit-fentanyl, was assessed by week across 
the study period. All data analyses were conducted using SAS v. 9.3. (22)
Results
In total, 12.9% (n=69) of the 536 OD deaths involved illicit-fentanyl and 87.1% (n=467) 
involved other drugs. Illicit-fentanyl deaths included those whose primary (n=51) or 
contributing (n=1) cause of death involved illicit fentanyl, and those with a pending/non-
specific cause of death for whom fentanyl was detected via toxicology tests (n=23). 
Decedents that filled fentanyl prescriptions within 90 days of their death (n=6) were 
considered part of the other-drug group (Figure 1).
While illicit-fentanyl deaths were reported throughout the study period, two notable 
increases were identified in March – April 2013 (weeks 61–74) and November 2013 – 
March 2014 (weeks 98–115) (Figure 2). These correspond to a previously reported outbreak 
of OD deaths involving acetyl fentanyl in northeast RI (1) and the increase in ODs involving 
fentanyl that resulted in this public health response. (23)
Socio-demographic Characteristics
Decedents’ ages ranged between 17 and 86 years, with a median age of 45 years. Most 
decedents were male (68.1%), non-Hispanic white (87.1%), and single (49.3%). Nearly 7% 
of decedents were known to be military veterans. No statistically significant differences in 
sex, race and ethnicity, marital or veteran status were found between decedents whose deaths 
involved illicit-fentanyl vs. other-drugs. However, illicit-fentanyl decedents were 
significantly younger than other-drug decedents (p=0.005); a third of illicit-fentanyl 
decedents were between 26 and 35 years old (34.8%, n=24) (Table 1).
Toxicological Evidence of Substance Use
At the time of death, 63% (n=336) of all decedents had at least one non-fentanyl-related 
illicit substance present in their bodies; illicit-fentanyl (58.0%) and other-drug deaths 
(63.4%) did not differ in whether they had non-fentanyl-related illicit substances in their 
toxicology report. Postmortem toxicological evidence of illicit substance use among all 
decedents was highest for illicit substances that are frequently injected, such as cocaine and 
Mercado et al. Page 6













heroin. The difference in toxicological evidence of cocaine among illicit-fentanyl (39.1%) 
and other-drug (30.4%) deaths was not statistically significant. However, significantly more 
other-drug (31.9%) than illicit-fentanyl (18.8%) deaths had toxicological evidence of heroin 
consumption (p=0.000). Additionally, significantly higher proportions of other-drug than 
illicit-fentanyl deaths had toxicological evidence of consuming pharmaceutical opioids (i.e., 
codeine, methadone, morphine, oxycodone) (Table 2).
Reported Recent Substance Abuse
Third-party reports (e.g., family, friends, medical records) showed that nearly half of all 
decedents had a recent history of alcohol (48.3%), tobacco (44.6%) or any type of illicit drug 
use (47.8%). Significantly more illicit-fentanyl than other-drug decedents were reported to 
be recent users of any type of illicit drugs (62.3% v. 45.6%, p=0.002) and, specifically, 
heroin (49.3% v. 28.3%, p=0.000). Over 13% of all decedents had reports of prior OD, and 
18.1% were reported to have undergone any type of drug treatment or rehabilitation at least 
once (Table 2).
Recent Opioid Prescription History
Of the 536 decedents in this study, 186 (34.7%) had at least one opioid prescription filled 
within 90 days of death – accounting for a nearly identical proportion among illicit-fentanyl 
and other-drug deaths (Table 2). Nearly a third (32.8%) of all decedents with opioid 
prescriptions were prescribed more than 100 MME/day, placing them at increased risk for 
OD (Table 3). Among 26–35 year olds, only 24.8% (n=27) filled at least one opioid 
prescription within 90 days of death, yet 70.4% (n=19) in this age group were prescribed 
more than 100 MME/day (mean, 108.7 MME/day) (data not shown).
On average, decedents who filled at least one opioid prescription within 90 days of death 
filled 7.3 (s.e.=0.2) opioid prescriptions, with a median 85.1 MME/day (mean (x̄)=45.1, 
s.e.=4.9) during that period. Decedents whose deaths involved other-drugs filled 
significantly more opioid prescriptions (x ̄ ± s.e.= 7.5 ± 0.2 v. 6.0 ± 0.4; p=0.001) with 
higher MME/per day (x̄ ± s.e.= 148.5 ± 5.3 v. 114.2 ± 9.9; p=0.039) than those whose 
deaths involved illicit-fentanyl (Table 3). Illicit-fentanyl decedents (29.2%) filled 
significantly more prescriptions for buprenorphine – an opioid partial antagonist utilized in 
medication assisted treatments (MAT) for drug addiction – than other-drug decedents 
(10.5%; p=0.019) (Table 4). This includes 37.5% of all 26–35 year old illicit-fentanyl 
decedents. Over half of 26–35 year olds also filled oxycodone (59.3%; n=16) and 
hydrocodone (51.9%; n=14) prescriptions within 90 days of death (data not shown). 
Differences in other opioid prescriptions filled by decedents were not statistically significant 
(Table 4).
Multiple Provider Episodes
Most decedents did not have multiple provider episodes (≥ 3 prescribers or dispensers). Over 
75% of all decedents who filled opioid prescriptions within 90 days of death (75.8%) 
obtained these from 1–2 prescribers; only 24.2% filled opioids provided by 3 or more 
prescribers. On average, decedents whose deaths involved other drugs filled prescriptions 
from more prescribers than illicit-fentanyl decedents (x ̄ ± s.e.= 2.6 ± 0.1 v. 1.9 ± 0.2; 
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p=0.000) (Table 3). Young adults ages 26–35 years filled opioid prescriptions provided 
mostly by 1–2 prescribers (85.2%, n=23) (data not shown).
The majority of decedents who filled opioid prescriptions within 90 days of death (83.9%) 
did so at 1–2 dispensers (e.g., pharmacies); 16.1% filled them at 3 or more dispensers. On 
average, decedents whose deaths involved other drugs obtained these at more dispensers 
than illicit-fentanyl decedents (x̄ ± s.e.= 2.0 ± 0.0 v. 1.5 ± 0.1; p=0.000) (Table 3). Young 
adults ages 26–35 years filled these opioid prescriptions at 1–2 dispensers (81.5%, n=22) 
(data not shown).
Discussion
Illicit-fentanyl deaths were often associated with other illicit drugs that are frequently 
injected (i.e., heroin, cocaine). Significantly more other-drug than illicit-fentanyl deaths had 
toxicological evidence of heroin and various pharmaceutical substances. Yet, third-party 
reports of decedents’ recent substance abuse found that significantly more decedents whose 
deaths involved illicit-fentanyl than other-drug decedents were recent users of any type of 
illicit substance, and specifically heroin. Furthermore, the proportion of all decedents who 
filled opioid prescriptions at levels considered high risk for overdose (>100 MME/day) 
within 90 days of death is concerning.
Apart from illicit-fentanyl decedents being significantly younger than other-drug decedents, 
no other socio-demographic differences were identified. Overall, decedents’ socio-
demographic characteristics were consistent with the literature; most were non-Hispanic 
white and male. (11) On average, other-drug decedents obtained opioid prescriptions from 
significantly more prescribers and/or dispensers than illicit-fentanyl decedents; multiple 
provider episodes were not a significant risk factor for illicit-fentanyl ODs. This suggests 
that perhaps illicit-fentanyl decedents were further along in the opioid abuse trajectory – 
relying less on prescription opioids and more on illicit drugs – and at a younger age, 
compared to other-drug decedents.
Significantly more decedents whose deaths involved illicit-fentanyl had third-party reports 
of recent illicit drug use – especially of heroin – than other-drug decedents. In fact, nearly 
20% of illicit-fentanyl deaths had postmortem toxicological evidence of heroin and over a 
third had evidence of cocaine in their bodies. Yet significantly more other-drug (31.9%) than 
illicit-fentanyl (18.8%) deaths had toxicological evidence of heroin consumption. 
Limitations in the study’s heroin case definition and data sources could have resulted in 
illicit-fentanyl deaths that tested positive for morphine not being classified as heroin positive 
by the time the study’s data was collected (i.e., 3 out of 16 total morphine positive illicit-
fentanyl deaths).
Illicit-fentanyl deaths were not solely associated with consuming one particular type of non-
fentanyl illicit substance. This is consistent with findings from law enforcement 
investigations, which suggest illicit-fentanyl deaths were mostly associated with illicit 
injection drug use, with the illicit fentanyl or fentanyl analog being used alone, in place of, 
at the same time as, or mixed with heroin (e.g., fentanyl-tainted heroin).
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It is notable that among all decedents with opioid prescriptions, approximately one-third 
received >100 MME/day within 90 days of death. It is especially concerning that among 
young decedents (26–35 years) with opioid prescriptions, over 70% were prescribed >100 
MME/day. Furthermore, these prescriptions were mostly provided to each decedent by a 
single prescriber and dispenser, not multiple providers. Additionally, over half of 26–35 year 
old decedents with opioid prescriptions had been prescribed buprenorphine within the same 
time period; they were likely receiving MAT for opioid use disorders. Prescriptions for 
opioids to treat pain should be closely monitored since the combination of buprenorphine 
with other opioids, whether illicit or prescription, could raise the MME to levels associated 
with increased risk of overdose. Considering this and the fact that over 34% of illicit-
fentanyl decedents were 26–35 years old at the time of death, this study’s findings 
disturbingly suggest these young decedents started the opioid abuse trajectory (i.e., 
prescription opioids to illicit drugs) at a younger age and with a fast-approaching fatal 
outcome.
Study Limitations
This study was subject to at least four limitations. First, analyses are limited to the data that 
were abstracted while in the field during this public health emergency response 
investigation, which occurred while the outbreak was ongoing; some decedents’ primary and 
contributing causes of death were still pending or under review. The study’s case definition 
considers this limitation, and allows for illicit-fentanyl and other-drug decedents to be 
classified based on preliminary toxicology findings.
Second, inconsistencies in the documentation or availability of information for each 
decedent could have affected the study’s findings, especially decedents’ history of substance 
abuse. This information was gathered by the OSME postmortem, based on third-party 
interviews and/or findings from death scene investigations. As such, our study likely 
underestimates substance abuse across all decedents.
Third, prescription data were obtained by searching for each decedent by name and date of 
birth, via RI’s PMP secure query system. This produced records with multiple residential 
addresses for most decedents. It was not possible to confirm whether these decedents had 
changed residence, or if prescription data for multiple individuals with the same name and 
date of birth was being produced by RI’s PMP query system. Also, it is not possible to know 
if all opioid prescriptions filled by decedents were consumed by them, nor if they obtained 
opioid prescriptions through illicit means (e.g., black market).
Finally, toxicological analyses are unable to distinguish between pharmaceutical and illicitly 
manufactured fentanyl. Therefore, it was not possible to determine if illicit-fentanyl 
decedents consumed illicitly manufactured fentanyl – a suspected contributor to recent 
increases in heroin-related deaths (24) –, or illicitly acquired pharmaceutical fentanyl.
Conclusions
In 2012, Rhode Island ranked 19th in prescribing opioid pain relievers (89.6 opioid 
prescriptions per 100 persons) and 17th in prescribing high-dose opioid pain relievers (5.2 
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per 100). (25) However, this study’s fentanyl-related deaths were associated with the use of 
illicit fentanyl and other drugs that are frequently injected (e.g., heroin, cocaine). Yet, the 
high overdose risk levels of MME/day prescribed within 90 days of death is concerning; the 
risk is even greater when heroin or illicit fentanyl is used simultaneously with prescription 
opioids. This outbreak occurred within the context of the current heroin epidemic in the US, 
driven by the increase in prescription opioid use for non-medical purposes (11), and heroin’s 
higher availability, lower cost and increased purity. (10, 11)
Collaborations between law enforcement, public health, health care, and recovery/treatment 
sectors are needed to reduce access to illicit drugs (e.g., heroin, cocaine), including illicitly 
manufactured or obtained fentanyl, and help those in need to recover from substance use 
disorders. Medication assisted treatment (MAT) is recommended for patients struggling with 
substance abuse, including abuse of illicit and prescription opioids; people who abuse 
prescription opioids are 40 times more likely to also abuse heroin. (11) Reviewing patient’s 
prescription and illicit substance abuse history prior to starting MAT is advised; 
subsequently, monitoring PMP data and routine urine drug testing for specific substances 
(e.g., buprenorphine, heroin, prescription opioids, cocaine, benzodiazepines) is 
recommended. (26, 27) Increasing first-responder, family member, and opioid user access to 
opioid antagonists (e.g., naloxone) can also reduce overdoses and improve opioid safety. (11, 
28)
Addressing pain is an important part of clinical care; it is estimated that 11.2% of people in 
the US suffer from chronic pain. (29) While diverse non-opioid treatment options for acute 
and chronic pain exist (e.g., physical therapy, non-steroidal anti-inflammatory drugs) and 
should be considered prior to starting an opioid treatment regimen, the benefits of opioid 
medications may occasionally outweigh the risks. Given the strong association between 
prescription opioid abuse and abuse of illicit drugs such as heroin, it is imperative that 
prescribers and dispensers ensure patients’ safety when utilizing opioid medications.
Providers should assess patients’ substance abuse history and risk for abuse prior to 
prescribing opioids and start with the lowest effective dose (30, 31, 32), during a pre-
determined timeframe 30, 32). Prescribers should monitor the patients’ pain intensity (30, 
31), level of functioning (30, 31, 32), and evidence of aberrant behaviors or adverse effects 
(30, 31). It is important for prescribers to ensure patients receive appropriate pain treatment, 
while preventing or reducing their risk for adverse outcomes. Illicit, non-prescription opioids 
are not always sought for recreational purposes; sometimes they are sought as an alternate 
mechanism for pain control.
Additionally, it is recommended that prescribers and dispensers verify patients’ prescription 
drug history prior to dispensing opioids. PMPs are a useful tool for this task. Given the 
relationship between heroin and prescription opioid abuse, (33, 34) these actions – in 
conjunction with following guidelines for opioid prescribing–might reduce both heroin and 
prescription opioid abuse and overdoses. Utilizing PMP data to identify prescribers and 
dispensers associated with opioid overdose deaths and patients with high MME/day is also 
recommended.
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Study Population: Drug Overdose (OD) Deaths in Rhode Island (RI), January 2012 – March 
2014.
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Number of Drug Overdose Deaths, by Week of Death – Rhode Island, January 2012 – 
March 2014 (N=536).
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Table 1







Illicit-Fentanyl (N=69) Other-Drug (N=467)
Age, in Years (median=45, min=17, max=86)
 17–20 years 9 (1.7) 4 (5.8) 5 (1.1)
0.005*
 21–25 years 31 (5.8) 4 (5.8) 27 (5.8)
 26–35 years 109 (20.3) 24 (34.8) 85 (18.2)
 36–45 years 123 (23.0) 13 (18.8) 110 (23.5)
 46–55 years 171 (31.9) 15 (21.7) 156 (33.4)
 56–65 years 82 (15.3) 9 (13.0) 73 (15.6)
 Over 65 years 11 (2.1) 0 11 (2.4)
Sex
 Female 150 (28.0) 21 (30.4) 129 (27.6)
0.061 Male 365 (68.1) 42 (60.9) 323 (69.2)
 Unknown 21 (3.9) 6 (8.7) 15 (3.2)
Race and Ethnicity
 Non-Hispanic Black 25 (4.7) 3 (4.4) 22 (4.7)
0.941*
 Non-Hispanic White 467 (87.1) 61 (88.4) 406 (86.9)
 Hispanic 38 (7.1) 4 (5.8) 34 (7.3)
 Other 6 (1.1) 1 (1.5) 5 (1.1)
Marital Status
 Divorced or Widowed 146 (27.2) 14 (20.3) 132 (28.3)
0.130
 Married 98 (18.3) 9 (13.0) 89 (19.1)
 Single 264 (49.3) 40 (58.0) 224 (48.0)
 Unknown 28 (5.2) 6 (8.7) 22 (4.7)
Veteran Status
 No 475 (88.6) 60 (87.0) 415 (88.9)
0.164* Yes 37 (6.9) 3 (4.4) 34 (7.3)
 Unknown 24 (4.5) 6 (8.7) 18 (3.9)
Notes: Percentages refer to the proportion of decedents represented within illicit-fentanyl and other-drug overdose deaths (i.e., column 
percentages). Bold indicates that differences between illicit-fentanyl and other-drug decedents are statistically significant.
*
Denotes Fisher Exact test, due to small expected cell counts.
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